AnaptysBio completed the spin-off of First Tracks Biotherapeutics on April 20, 2026. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio held as of April 6, 2026. First Tracks began trading on the Nasdaq under the ticker symbol TRAX on April 20, 2026. The filing provides unaudited pro forma financial information to illustrate the impact of the separation on AnaptysBio's continuing operations. AnaptysBio provided a $100 million cash distribution to First Tracks as part of the separation.